TY - JOUR T1 - Genetic and atherosclerotic plaque immunohistochemical analyses do not associate reduced sclerostin expression with cardiovascular events JF - medRxiv DO - 10.1101/2020.11.20.20235234 SP - 2020.11.20.20235234 AU - Gill Holdsworth AU - James R Staley AU - Peter Hall AU - Ian van Koeverden AU - Ciara Vangjeli AU - Remi Okoye AU - Rogely Boyce AU - James R Turk AU - Martin Armstrong AU - Alison Wolfreys AU - Gerard Pasterkamp Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/23/2020.11.20.20235234.abstract N2 - The sclerostin antibody romosozumab increases bone formation and decreases bone resorption, leading to increased bone mass, bone mineral density and bone strength, and reduced fracture risk. In a clinical study versus alendronate in postmenopausal women (ARCH), an imbalance in adjudicated serious cardiovascular (CV) events driven by an increase in myocardial infarction (MI) and stroke was observed.To investigate whether inhibition of sclerostin in atherosclerotic plaques may have contributed to this imbalance, sclerostin was immunostained in human plaques to determine whether it was detected in regions relevant to plaque stability. Additionally, genetic variants associated with lifelong reduced sclerostin expression were explored for associations with phenotypes including those related to bone physiology and CV risk factors/events in a population-based phenome-wide association study (PheWAS).Sclerostin expression was absent (67%) or reduced in atherosclerotic plaques and when present was in deeper regions of the plaque/wall and not in areas considered relevant to plaque stability (fibrous cap and endothelium). Natural genetic modulation of sclerostin by variants with a significant positive effect on bone physiology showed no association with lifetime risk of MI or stroke. These data do not support a causal association between sclerostin inhibition and increased risk of serious cardiovascular events.Competing Interest StatementGH, JRS, PH, CV, RO, MA, AW are employees of UCB Pharma and may hold stock/stock awards; RB, JRT are/have been employees of Amgen Inc. and may hold stock/stock awards.Funding StatementThis work was funded by UCB Pharma and Amgen Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All genetic association results used in the genetic analyses were obtained from the public domain. Samples from the AtheroExpress biobank had been collected from patients who had given written informed consent as previously described; Medical Ethical Committees of the participating studies have approved those studies. Further details can be found in Verhoeven et al. doi: 10.1007/s10564-004-2304-6. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets generated during and/or analysed during this study which were not included as supplementary files are available from the corresponding author on reasonable request. ER -